AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28569122
Drug: Fingolimod combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod combined with bridging therapy
Trial: 9871428
Drug: GI198745 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI198745 (0.1 to 40 mg)
Trial: 57340
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of steroid drugs
Trial: 325726
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of steroid drugs + 600 rads of radiotherapy to the graft
Trial: 30759457
Drug: Nasal valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal valve lift treatment using absorbable, polylactic acid, self‐retaining cone threads (Silhouette Soft)
Trial: 30759457
Drug: Nasal valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal valve lift treatment using absorbable, polylactic acid, self‐retaining cone threads (Silhouette Soft) + turbinoplasty
Trial: 19032566
Drug: Colloid boluses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid boluses of 200 ml until stroke volume did not increase >or=10%
Trial: 15016643
Drug: CHOP‐21 (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP‐21 (standard chemotherapy every 3 weeks)
Trial: 15016643
Drug: CHOEP‐21 (CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOEP‐21 (CHOP plus etoposide 100 mg/m2 days 1‐3)
Trial: 15016643
Drug: CHOP‐14 (biweekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP‐14 (biweekly chemotherapy)
Trial: 11757689
Drug: Triple eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple eradication therapy (Clarithromycin 500 mg/d, Metronidazol 800 mg/d, Omeprazol 40 mg/d for 7 days)
Trial: 29185480
Drug: JNJ‐39393406 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐39393406 (100 mg b.i.d.)
Trial: 24423155
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day TTP488
Trial: 24423155
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day TTP488
Trial: 24423155
Drug: TTP488 plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTP488 plasma concentrations (7.6-16.8 ng/mL)
Trial: 24423155
Drug: TTP488 plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTP488 plasma concentrations (46.8-167.0 ng/mL)
Trial: 22188544
Drug: Clopidogrel hydrogen
RxNorm normalized name: Clopidogrel hydrogen sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel hydrogen sulfate (CHS) 600 mg loading dose followed by 75 mg/day
Trial: 22188544
Drug: Clopidogrel besylate
RxNorm normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel besylate (CB) 600 mg loading dose followed by 75 mg/day
Trial: 17485382
Drug: Post transplant
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post transplant maintenance and targeted conditioning therapies such as bone seeking radioisotopes.
Trial: 10560446
Drug: Belief in
RxNorm normalized name: Ora Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belief in clinical trials increasing knowledge about treatment options
Trial: 10560446
Drug: Desire for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desire for optimum treatment for patients
Trial: 3552010
Drug: Diazemuls (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazemuls (0.15 mg kg‐1)
Trial: 6136290
Drug: Midazolam (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.07 mg kg‐1)
Trial: 31646475
Drug: Nebulized dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized dexamethasone 8 mg 1 hour before surgery
Trial: 16800343
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy using Cisplatin and Etoposide along with Wobe Mugos E
Trial: 16800343
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy using Cisplatin and Etoposide
Trial: 10925060
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two sympathetic tests
Trial: 10925060
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all five tests
Trial: 6105118
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g daily sulphasalazine
Trial: 6105118
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g daily sulphasalazine
Trial: 6105118
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g daily sulphasalazine
Trial: 30008106
Drug: High-protein nutrient
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein nutrient preload (50-g Parmesan cheese, one boiled egg, and 300-ml water)
Trial: 30008106
Drug: Water (500-ml)
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (500-ml)
Trial: 21239636
Drug: Low-dose spironolactone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spironolactone (∼1 mg·kg(‐1)·day(‐1))
Trial: 21239636
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose spironolactone (∼30 mg·kg(‐1)·day(‐1))
Trial: 14688530
Drug: Sirolimus monotherapy
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus monotherapy (n=11)
Trial: 14688530
Drug: Calcineurin inhibitors
RxNorm normalized name: Calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitors (n=12)
Trial: 9315493
Drug: Yohimbine hydrochloride
RxNorm normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine hydrochloride (30 mg/day, two 5 mg tablets three times daily for eight weeks)
Trial: 7964947
Drug: rIFN‐gamma at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN‐gamma at a dose of 4 x 10(6) U subcutaneously per day for 6 months
Trial: 7964947
Drug: rIFN‐gamma treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN‐gamma treatment
Trial: 3301260
Drug: Five bio‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five bio‐ or semisynthetic human insulins (specific preparations not detailed) tested at equal dosages.
Trial: 20962913
Drug: Protein plus
RxNorm normalized name: Nutritional Supplement Oral Tablet [SAMSON PROTEIN PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein plus carbohydrate (PRO) beverage (40 g carbohydrate, 20 g whey protein)
Trial: 20962913
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) beverage (60 g)
Trial: 9341603
Drug: Flutamide 250
RxNorm normalized name: flutamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide 250 mg/d
Trial: 6143975
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 2 X 10(6) units IFN‐beta for 10 consecutive days
Trial: 6143975
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections for 10 consecutive days
Trial: 6143975
Drug: IFN‐beta treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐beta treatment for non-responders after 3 months
Trial: 6143975
Drug: IFN‐beta treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐beta treatment
Trial: 6143975
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of IFN‐beta
Trial: 29059367
Drug: Metabolism-informed care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolism-informed care (MIC)
Trial: 22227851
Drug: 1,000 mL
RxNorm normalized name: container,empty 1,000 mL MISCELL BOTTLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mL of milk
Trial: 22227851
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of milk
Trial: 19606529
Drug: Clozapine (250-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (250-600 mg/day)
Trial: 17891598
Drug: No GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No GnRH agonist
Trial: 14713745
Drug: Various agents
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various agents including dietary supplements, finasteride, and cyclooxygenase-2 inhibitors
Trial: 8074071
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg cholecalciferol
Trial: 8074071
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg cholecalciferol
Trial: 8074071
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg cholecalciferol every 3 months
Trial: 21482217
Drug: Amlodipine/valsartan 10/320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan 10/320 mg (intensive)
Trial: 21482217
Drug: Amlodipine/valsartan 5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan 5/160 mg (moderate)
Trial: 15715034
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (two 20 min sessions per week for 16 weeks)
Trial: 15715034
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation (self-administered sessions on the same schedule)
Trial: 11280830
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate 1 g/day continuous infusion up to postoperative day 4
Trial: 11280830
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate 1 g/day continuous infusion plus octreotide 0.1 mg every 8 hours for 5 days
Trial: 10322862
Drug: Tongxinluo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo capsule (TXLC), 4 capsules, three times daily
Trial: 10322862
Drug: Shuxin oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxin oral liquor (SXOL), 20 ml, two times daily
Trial: 8233513
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (isometric strengthening exercises) for 8 weeks followed by 8 weeks of VR
Trial: 25479285
Drug: Text messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messaging (daily for 2 weeks, alternate days for 2 weeks, weekly thereafter for 22 weeks)
Trial: 22715822
Drug: 3% thyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% thyme essential oil antifungal cream
Trial: 22715822
Drug: 10% chamomile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% chamomile extract cream
Trial: 12169173
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SIT) with standardized Dermatophagoides pteronyssinus extract for 3 years
Trial: 6153835
Drug: Corticosteroid ointments
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid ointments (20 tested)
Trial: 6153835
Drug: Corticosteroid creams
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid creams (19 tested)
Trial: 6153835
Drug: Hydrocortisone preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone preparations (tested with occlusion)
Trial: 6153835
Drug: Other corticosteroid
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other corticosteroid preparations (tested with and without occlusion)
Trial: 30700068
Drug: Exercise and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise and Manipulation Therapy (EMT)
Trial: 24913818
Drug: Broccoli sprout
RxNorm normalized name: BROCCOLI SPROUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli sprout beverage providing daily doses of 600 μmol glucoraphanin and 40 μmol sulforaphane
Trial: 14760893
Drug: Nelfinavir/nevirapine (1250/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir/nevirapine (1250/200 mg twice daily)
Trial: 14760893
Drug: Ritonavir/saquinavir (400/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir/saquinavir (400/400 mg twice daily)
Trial: 2060563
Drug: lormetazepam 0.5
RxNorm normalized name: lormetazepam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lormetazepam 0.5 mg
Trial: 30648524
Drug: Combined glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined glucosamine hydrochloride plus chondroitin sulfate (GH+CS) 1500 mg + 1200 mg daily for 6 months
Trial: 30576794
Drug: Tanezumab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab treatment with NSAIDs <90 days (limited NSAID users)
Trial: 30576794
Drug: Tanezumab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab treatment with NSAIDs ≥90 days (chronic NSAID users)
Trial: 26600646
Drug: Conventional Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Oral Examination (COE)
Trial: 22250063
Drug: Flavonoid-enriched chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonoid-enriched chocolate (27 g/day, containing 850 mg flavan-3-ols and 100 mg isoflavones)
Trial: 10212711
Drug: PCEA (parturient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA (parturient-controlled epidural analgesia) - bolus 5 ml, lockout 15 minutes
Trial: 10212711
Drug: CIEA (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIEA (continuous infusion epidural analgesia) - 8 ml/h
Trial: 7832129
Drug: Tissue plasminogen
RxNorm normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tissue plasminogen activator, anistreplase, or both (exact dosage and duration not specified)
Trial: 15190231
Drug: Levodopa (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (single dose)
Trial: 2078983
Drug: Haloperidol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (single dose)
Trial: 31951261
Drug: eGFR ≤60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR ≤60 mL/min/1.73 m2
Trial: 31951261
Drug: eGFR =
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR = 45 mL/min/1.73 m2
Trial: 31951261
Drug: eGFR <75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR <75 mL/min/1.73 m2
Trial: 31951261
Drug: eGFR ≥75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR ≥75 mL/min/1.73 m2
Trial: 30663038
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen (30-70 l.min-1)
Trial: 30663038
Drug: Standard flow-rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard flow-rate facemask (15 l.min-1)
Trial: 23910386
Drug: Nano-hydroxyapatite-coated mini-implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-hydroxyapatite-coated mini-implants
Trial: 23910386
Drug: Commercially pure
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially pure titanium mini-implants
Trial: 23910386
Drug: Both implant
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both implant surfaces (nano-hydroxyapatite-coated and cp titanium)
Trial: 23362969
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg early induction regimen (weeks 0, 1, 2, 4)
Trial: 23362969
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg monthly induction regimen (weeks 0, 4, 8)
Trial: 23362969
Drug: Fixed-interval secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed-interval secukinumab (150 mg at weeks 12 and 24)
Trial: 23362969
Drug: Start-of-relapse secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Start-of-relapse secukinumab (150 mg at visits at which a start of relapse was observed)
Trial: 21143704
Drug: Gabapentin (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (starting dose 300 mg once daily to a target of 900 mg daily)
Trial: 14972420
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) at standard dose (600mg orally twice daily; SD Group; n=110)
Trial: 14972420
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) at double dose (1200mg orally twice daily; DD Group; n=114)
Trial: 14972420
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) at standard dose (SD Group)
Trial: 14972420
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) at double dose (DD Group)
Trial: 11856901
Drug: Hypericum (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum (900 mg)
Trial: 11856901
Drug: Hypericum (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum (1800 mg)
Trial: 29569389
Drug: SeR-Se-Ly (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SeR-Se-Ly (1 tablet daily for 6 months)
Trial: 29569389
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg (1 tablet daily for 6 months)
Trial: 24273971
Drug: Danzhi Xiaoyao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danzhi Xiaoyao Pill (DXP) in addition to Metformin and Diane-35
Trial: 24273971
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and Diane-35 (Control Group B)
Trial: 16530767
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 100 mg/day on days 1-5 of the menstrual cycle (group 1)
Trial: 16530767
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 100 mg/day on days 5-9 of the menstrual cycle (group 2)
Trial: 7652983
Drug: Local anaesthesia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthesia with 20 ml of 1% lidocaine
Trial: 7652983
Drug: Intravenous anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anaesthesia with pethidine/diazepam
Trial: 31247980
Drug: Conventional cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cocoa (CC) 15 g in 200 mL of semi-skimmed milk containing 19.80 mg of flavanols
Trial: 31247980
Drug: Flavanol-rich cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanol-rich cocoa (CC-PP) 25 g in 200 mL of semi-skimmed milk containing 68.25 mg of flavanols
Trial: 21873708
Drug: Warfarin (dose-adjusted,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (dose-adjusted, target INR 2.0-3.0)
Trial: 20329617
Drug: L-dopa and
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa and ephedrine, orally 1 hour before sexual intercourse for 45 days.
Trial: 20329617
Drug: L-dopa and
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa and ephedrine
Trial: 7918132
Drug: Isradipine 10
RxNorm normalized name: isradipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 10 mg bid
Trial: 2830189
Drug: Enalapril, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 20 mg daily for 6 weeks
Trial: 2830189
Drug: Diltiazem, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem, 120 mg daily for 6 weeks
Trial: 2830189
Drug: Nifedipine, 10
RxNorm normalized name: Nifedipine, 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 10 mg p.o. during washout phase
Trial: 2830189
Drug: Enalaprilat, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat, 5 mg i.v. during washout phase
Trial: 30963177
Drug: Nutrition (child
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition (child nutrition counseling plus lipid-based nutrient supplements)
Trial: 26421634
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo treatment
Trial: 26421634
Drug: Inactive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo treatment